A four-year survival update from Merck’s RATIONALE-307 program showed continued overall survival and progression-free survival benefits with tislelizumab plus chemotherapy in advanced squamous non-small cell lung cancer. While not cardiology-specific, the update comes as cardio-oncology scrutiny expands across immunotherapy combinations. Separately, a phase 1 trial combining ibrutinib with lenalidomide in relapsed chronic lymphocytic leukemia reported durable disease control alongside unexpected serious cardiac toxicities. The safety signal is likely to matter for clinicians and trial designers as they evaluate cardiac risk tradeoffs when stacking BTK inhibition with other immune-modulating agents. The combined message for the industry: long-horizon efficacy reporting is increasingly paired with heightened vigilance around cardiotoxicity, especially in immune and combination regimens.